Cargando…
Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
PURPOSE: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β(2)-agonists), β-blockers, or β-blocker–β-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHO...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783502/ https://www.ncbi.nlm.nih.gov/pubmed/24072964 http://dx.doi.org/10.2147/CIA.S49644 |
_version_ | 1782285680883269632 |
---|---|
author | Zeng, Long-Huan Hu, Yi-Xin Liu, Lin Zhang, Meng Cui, Hua |
author_facet | Zeng, Long-Huan Hu, Yi-Xin Liu, Lin Zhang, Meng Cui, Hua |
author_sort | Zeng, Long-Huan |
collection | PubMed |
description | PURPOSE: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β(2)-agonists), β-blockers, or β-blocker–β-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: This was a retrospective cohort study of 220 elderly male COPD patients (mean age 84.1 ± 6.9 years). The patients were divided into four groups on the basis of the use of β-blockers and β(2)-agonists. N-terminal fragment pro-B-type natriuretic peptide (NT pro-BNP), left ventricular ejection fraction (LVEF), and other relevant parameters were measured and recorded. At follow-up, the primary end point was all-cause mortality. RESULTS: Multiple linear regression analysis revealed no significant associations between NT pro-BNP and the use of β(2)-agonists (β = 35.502, P = 0.905), β-blockers (β = 3.533, P = 0.989), or combination therapy (β = 298.635, P = 0.325). LVEF was not significantly associated with the use of β(2)-agonists (β = −0.360, P = 0.475), β-blockers (β = −0.411, P = 0.284), or combination therapy (β = −0.397, P = 0.435). Over the follow-up period, 52 patients died, but there was no significant difference in mortality among the four groups (P = 0.357). Kaplan–Meier analysis showed no significant difference among the study groups (log-rank test, P = 0.362). After further multivariate adjustment, use of β(2)-agonists (hazard ratio [HR] 0.711, 95% confidence interval [CI] 0.287–1.759; P = 0.460), β-blockers (HR 0.962, 95% CI 0.405–2.285; P = 0.930), or combination therapy (HR 0.638, 95% CI 0.241–1.689; P < 0.366) were likewise not correlated with mortality. CONCLUSION: There was no association between the use of β(2)-agonists, β-blockers, or β-blocker-β(2)-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients, which indicated that they may be used safely in this population. |
format | Online Article Text |
id | pubmed-3783502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-37835022013-09-26 Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease Zeng, Long-Huan Hu, Yi-Xin Liu, Lin Zhang, Meng Cui, Hua Clin Interv Aging Original Research PURPOSE: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β(2)-agonists), β-blockers, or β-blocker–β-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: This was a retrospective cohort study of 220 elderly male COPD patients (mean age 84.1 ± 6.9 years). The patients were divided into four groups on the basis of the use of β-blockers and β(2)-agonists. N-terminal fragment pro-B-type natriuretic peptide (NT pro-BNP), left ventricular ejection fraction (LVEF), and other relevant parameters were measured and recorded. At follow-up, the primary end point was all-cause mortality. RESULTS: Multiple linear regression analysis revealed no significant associations between NT pro-BNP and the use of β(2)-agonists (β = 35.502, P = 0.905), β-blockers (β = 3.533, P = 0.989), or combination therapy (β = 298.635, P = 0.325). LVEF was not significantly associated with the use of β(2)-agonists (β = −0.360, P = 0.475), β-blockers (β = −0.411, P = 0.284), or combination therapy (β = −0.397, P = 0.435). Over the follow-up period, 52 patients died, but there was no significant difference in mortality among the four groups (P = 0.357). Kaplan–Meier analysis showed no significant difference among the study groups (log-rank test, P = 0.362). After further multivariate adjustment, use of β(2)-agonists (hazard ratio [HR] 0.711, 95% confidence interval [CI] 0.287–1.759; P = 0.460), β-blockers (HR 0.962, 95% CI 0.405–2.285; P = 0.930), or combination therapy (HR 0.638, 95% CI 0.241–1.689; P < 0.366) were likewise not correlated with mortality. CONCLUSION: There was no association between the use of β(2)-agonists, β-blockers, or β-blocker-β(2)-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients, which indicated that they may be used safely in this population. Dove Medical Press 2013 2013-09-10 /pmc/articles/PMC3783502/ /pubmed/24072964 http://dx.doi.org/10.2147/CIA.S49644 Text en © 2013 Zeng et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed. |
spellingShingle | Original Research Zeng, Long-Huan Hu, Yi-Xin Liu, Lin Zhang, Meng Cui, Hua Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title | Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title_full | Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title_fullStr | Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title_full_unstemmed | Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title_short | Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
title_sort | impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783502/ https://www.ncbi.nlm.nih.gov/pubmed/24072964 http://dx.doi.org/10.2147/CIA.S49644 |
work_keys_str_mv | AT zenglonghuan impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT huyixin impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT liulin impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT zhangmeng impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease AT cuihua impactofbeta2agonistsbetablockersandtheircombinationoncardiacfunctioninelderlymalepatientswithchronicobstructivepulmonarydisease |